Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVC 203

Next Previous
Drug Profile

AVC 203

Alternative Names: Allo-QuadCAR01-T; AVC-203

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AvenCell Europe
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 16 Dec 2025 AvenCell Therapeutics plans a phase II QUADvance trial for Diffuse large B cell lymphoma (Second-line therapy or greater) in Germany (IV) (NCT07284433)
  • 04 Dec 2025 USFDA and EMA approves IND and CTA application for AVC 203 in B cell malignancies
  • 04 Dec 2025 AvenCell plans a phase I/II QUADvance trial for Lymphoid leukaemia and B-cell non-Hodgkin lymphoma (Second-line therapy or greater) (IV, Infusion) in USA, Germany and Europe in November 2025 (CTIS2025-521735-36-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top